Optina profile published in La PressePress article
Last January, Marc Tison from La Presse interviewed David Lapointe, Optina’s president. Mr. Lapointe did an overview of the hyperspectral camera technology and how it has the potential of diagnosing Alzheimer’s disease years before the appearance of the first symptoms. It is through a time-efficient and low-cost detection of the beta-amyloid protein that Optina stands out. This technology allows for the hope of large-scale screening.
See article here